Stephanie Halene MD, PhD

Assistant Professor of Medicine (Hematology)

Leukemia; myelodysplasia; myeloproliferative disorders; polycythemia; thrombocytosis; thrombocytopenia; sickle cell disease; thrombosis; coagulation

stephanie_halenefaculty-clinicsfalsetruefalse

Conditions	Study Title
Myelodysplastic Syndromes	Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered in a 72-Hour Continuous IV Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine.